标准化报告首次治疗后影像对头颈癌的预测价值
本研究回顾性分析199例头颈鳞状细胞癌患者,在治疗结束后12周行PET/CECT并按NI-RADS模板判读,随访至少9个月。结果显示NI-RADS分类从1增至3时治疗失败率分别为4.3%、9.1%和42.1%,Cox模型示NI-RADS分类与原发灶及颈部治疗失败均强相关。
要点
- 治疗后12周PET/CECT按NI-RADS判读可预测治疗失败风险。
- NI-RADS分类1、2、3对应治疗失败率分别为4.3%、9.1%、42.1%。
- NI-RADS分类与原发灶和颈部治疗失败均强相关。
核心结论
- 治疗后基线PET/CECT的NI-RADS分类升高与HNSCC患者治疗失败风险增加强相关。
研究设计与样本
- 回顾性队列研究,纳入2014年6月至2016年7月间完成治疗、治疗后12周行PET/CECT并按NI-RADS模板判读、且自治疗完成起随访9个月的患者,共199例,中位随访15.5个月。
主要发现
- 治疗失败率随NI-RADS分类从1增至3而升高,分别为4.3%、9.1%和42.1%。
- Cox比例风险模型显示NI-RADS分类与原发灶和颈部治疗失败均强相关,风险比分别为2.60和5.22,P < .001。
- 在手术治疗的亚组分析中,原发灶NI-RADS分类升高与治疗失败的关联未达统计学显著性,风险比0.88,P = .82。
关键数值与推荐
- 治疗失败定义为活检证实肿瘤阳性或符合实体瘤疗效评价标准(RECIST)的阳性。
- NI-RADS分类1、2、3对应的治疗失败率分别为4.3%、9.1%、42.1%。
- 原发灶和颈部NI-RADS分类与治疗失败的风险比分别为2.60和5.22,P < .001。
临床怎么用
- 可将治疗后12周PET/CECT的NI-RADS分类作为HNSCC治疗失败风险分层工具。
- NI-RADS分类越高提示治疗失败风险越高,可据此调整随访强度。
局限性
- 本研究为回顾性队列研究,样本来自单中心学术三级医院。
- 手术治疗亚组样本量较小,原发灶NI-RADS分类与治疗失败的关联未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Neck Imaging Reporting and Data System (NI-RADS) is a standardized numerical reporting template for surveillance of head and neck squamous cell carcinoma (HNSCC). Our aim was to analyze the accuracy of NI-RADS on the first posttreatment fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography (PET/CECT). STUDY DESIGN: Retrospective cohort study. SETTING: Academic tertiary hospital. SUBJECT AND METHODS: Patients with HNSCC with a 12-week posttreatment PET/CECT interpreted using the NI-RADS template and 9 months of clinical and radiologic follow-up starting from treatment completion between June 2014 and July 2016 were included. Treatment failure was defined as positive tumor confirmed by biopsy or Response Evaluation Criteria in Solid Tumors criteria. Cox proportional hazards models were performed. RESULTS: This study comprised 199 patients followed for a median of 15.5 months after treatment completion (25% quartile, 11.8 months; 75% quartile, 20.2 months). The rates of treatment failure increased with each incremental increase in NI-RADS category from 1 to 3 (4.3%, 9.1%, and 42.1%, respectively). A Cox proportional hazards model demonstrated a strong association between NI-RADS categories and treatment failure at both primary and neck sites (hazard ratio [HR], 2.60 and 5.22, respectively; P < .001). In the smaller treatment subgroup analysis, increasing NI-RADS category at the primary site in surgically treated patients and treatment failure did not achieve statistically significant association (HR, 0.88; P = .82). CONCLUSION: Increasing NI-RADS category at the baseline posttreatment PET/CECT is strongly associated with increased risk of treatment failure in patients with HNSCC.
引用
- Hsu D, Chokshi FH, Hudgins PA, et al. Predictive Value of First Posttreatment Imaging Using Standardized Reporting in Head and Neck Cancer. Otolaryngol Head Neck Surg. 2019. PMID: 31331239. doi:10.1177/0194599819865235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。